| Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma MB Overdijk, S Verploegen, M Bögels, M van Egmond, JJL van Bueren, ... MAbs 7 (2), 311-320, 2015 | 410 | 2015 |
| CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ... Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016 | 253 | 2016 |
| Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab IS Nijhof, RWJ Groen, HM Lokhorst, B Van Kessel, AC Bloem, ... Leukemia 29 (10), 2039-2049, 2015 | 222 | 2015 |
| The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking MB Overdijk, JHM Jansen, M Nederend, JJL van Bueren, RWJ Groen, ... The Journal of Immunology 197 (3), 807-813, 2016 | 220 | 2016 |
| Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia A Gutierrez, L Pan, RWJ Groen, F Baleydier, A Kentsis, J Marineau, ... The Journal of clinical investigation 124 (2), 644-655, 2014 | 184 | 2014 |
| A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ... Molecular therapy 25 (8), 1946-1958, 2017 | 165 | 2017 |
| Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib IS Nijhof, RWJ Groen, WA Noort, B van Kessel, R de Jong-Korlaar, ... Clinical cancer research 21 (12), 2802-2810, 2015 | 151 | 2015 |
| Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma RWJ Groen, WA Noort, RA Raymakers, HJ Prins, L Aalders, FM Hofhuis, ... Blood, The Journal of the American Society of Hematology 120 (3), e9-e16, 2012 | 137 | 2012 |
| Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab J Krejcik, KA Frerichs, IS Nijhof, B van Kessel, JF van Velzen, AC Bloem, ... Clinical cancer research 23 (24), 7498-7511, 2017 | 121 | 2017 |
| Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma E Drent, RWJ Groen, WA Noort, M Themeli, JJL van Bueren, PWHI Parren, ... haematologica 101 (5), 616, 2016 | 120 | 2016 |
| Non-canonical PRC1. 1 targets active genes independent of H3K27me3 and is essential for leukemogenesis V van den Boom, H Maat, M Geugien, AR López, AM Sotoca, J Jaques, ... Cell reports 14 (2), 332-346, 2016 | 110 | 2016 |
| Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma EPM Tjin, RWJ Groen, I Vogelzang, PWB Derksen, MD Klok, HP Meijer, ... Blood 107 (2), 760-768, 2006 | 106 | 2006 |
| Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor–engineered T cells E Drent, R Poels, R Ruiter, NWCJ van de Donk, S Zweegman, H Yuan, ... Clinical Cancer Research 25 (13), 4014-4025, 2019 | 76 | 2019 |
| Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease A Garcia-Gomez, D Quwaider, M Canavese, EM Ocio, Z Tian, JF Blanco, ... Clinical cancer research 20 (6), 1542-1554, 2014 | 72 | 2014 |
| Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma KA Kocemba, RWJ Groen, H Van Andel, MJ Kersten, K Mahtouk, ... PloS one 7 (2), e30359, 2012 | 70 | 2012 |
| Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches A Antonelli, WA Noort, J Jaques, B de Boer, R de Jong-Korlaar, ... Blood, The Journal of the American Society of Hematology 128 (25), 2949-2959, 2016 | 64 | 2016 |
| Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance J Sanne, NWCJ van de Donk, MC Minnema, JH Huang, T Aarts-Riemens, ... Clinical cancer research 19 (20), 5591-5601, 2013 | 64 | 2013 |
| CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia J Naik, M Themeli, R de Jong-Korlaar, RWJ Ruiter, PJ Poddighe, H Yuan, ... Haematologica 104 (3), e100, 2019 | 59 | 2019 |
| Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma RM Reijmers, RWJ Groen, H Rozemuller, A Kuil, A de Haan-Kramer, ... Blood, The Journal of the American Society of Hematology 115 (3), 601-604, 2010 | 58 | 2010 |
| Illegitimate WNT pathway activation by β-catenin mutation or autocrine stimulation in T-cell malignancies RWJ Groen, MECM Oud, EJM Schilder-Tol, MB Overdijk, D ten Berge, ... Cancer research 68 (17), 6969-6977, 2008 | 56 | 2008 |
Derk ten BergeAssociate Professor, dept of Cell Biology, Erasmus MC University Medical Center RotterdamGeverifieerd e-mailadres voor erasmusmc.nl
